Related Experiment Video
Updated: Oct 10, 2026

Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
Published on: November 23, 2017
Long-term ambient air pollution is not associated with circulating soluble urokinase plasminogen activator receptor
Bahjat Z Ghazzal1, Anis Ismail2, Yiyuan Huang3
1Department of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts.
Background:
Soluble urokinase plasminogen activator receptor (suPAR) is a stable chronic-inflammation biomarker causally implicated in atherosclerosis, yet its modifiable determinants remain largely uncharacterized. Long-term ambient air pollution is an established cardiovascular risk factor and a biologically plausible determinant of suPAR.
Methods:
In this cross-sectional analysis, we tested associations of long-term residential air pollution with circulating suPAR in 5,072 participants of the Multi-Ethnic Study of Atherosclerosis, drawn from six US metropolitan regions and enrolled during 2000-2002. Residential exposures were estimated with the validated Multi-Ethnic Study of Atherosclerosis Air spatiotemporal model, and serum suPAR was measured by enzyme-linked immunosorbent assay.
Results:
In multivariable linear regression adjusted for demographic, socioeconomic, and cardiovascular risk factors, neither fine particulate matter, nitrogen dioxide, nitrogen oxides, ozone, nor light-absorbing carbon was associated with suPAR; the fine particulate matter confidence interval excluded effect sizes of two percent or greater per 5 µg/m3.
Conclusions:
Together with two prior cohorts spanning two continents and three age ranges, these findings indicate that long-term ambient air pollution is unlikely to be a meaningful determinant of circulating suPAR or a major mediator of the air-pollution-cardiovascular-disease association, and suggest that the search for modifiable determinants of this clinically actionable biomarker should focus elsewhere.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Indirect-Acting Cholinergic Agonists: Pharmacokinetics
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they are...
